{"success":true,"data":{"pressRelease":{"id":"157248","rtpr_id":"nGNX1CKvpc-20260930","ticker":"ABVX","exchange":"Euronext Paris","all_tickers":["ABVX"],"title":"Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026","author":"Globe Newswire","published_at":"2026-09-30T20:05:00.622Z","article_body":"Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG)\nWeek 2026\n\nFour oral presentations and three posters build upon Phase 3 ABTECT\nMaintenance and Induction programs in ulcerative colitis, long-term Phase 2\nfindings, and preclinical anti-fibrotic research\n\nPARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA\n(https://www.globenewswire.com/Tracker?data=eISuOI7lWu37iIKE871_O0zyV1ZATSquQxSf1637j33XLrJZmlcmA6lY8zOF_nOY1bwIBJSyYfxIdxaxu3xMDQ==)\n(Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the\n“Company”), a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases,\ntoday announced that seven scientific abstracts on obefazimod, its lead drug\ncandidate for the treatment of moderately to severely active ulcerative\ncolitis (UC), will be presented at the United European Gastroenterology (UEG)\nWeek 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain.\nThese presentations will highlight data from the Phase 3 ABTECT Maintenance\nand Induction trials in UC, long-term follow-up from the Phase 2 program in\nUC, and preclinical research on obefazimod's anti-fibrotic and anti-tumor\nactivity.\n\n\"The data being presented at UEG Week add to the growing understanding of\nobefazimod and its potential in inflammatory bowel disease,” said Marc de\nGaridel, MBA, Chief Executive Officer of Abivax. “These findings reinforce\nour confidence in obefazimod’s potential to address significant unmet needs\nfor patients living with inflammatory bowel disease.\"\n\nChris Rabbat, PhD, Chief Medical Officer of Abivax, added, \"The seven accepted\nabstracts reflect the breadth and maturity of the obefazimod program, spanning\nPhase 3 maintenance results, long-term Phase 2 efficacy and safety data, and\npreclinical findings on inflammation and fibrosis. We look forward to sharing\nthese findings with the global gastroenterology community and highlighting the\ngrowing clinical and scientific evidence supporting obefazimod.”\n\nVisit the publications page of Abivax’s website to view the presentations\nafter the conclusion of the meeting.\n\nData to be Presented:\n\n Date & Time Session Room Abstract # Title Presenter \n Oral Presentation \n October 19, 10:50–11:00 Hot Topics in Clinical GI Research D3 OP097 Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance) Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai \n October 19, 10:50–11:00 Molecular Trajectories of Disease and Drug Responses in IBD A1 OP091 Obefazimod increases miR-124 expression to consistently modulate inflammation and fibrosis across preclinical models Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n October 19, 12:00–12:10 Long-term Outcomes of Interventional Trials in IBD A2 OP107 Long-term efficacy and persistence with obefazimod after dose de-escalation to 25 mg: 3-year interim analysis in patients with moderately to severely active ulcerative colitis completing Week 144, stratified by prior advanced therapy Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai \n experience: results from the Phase 2 program \n October 20, 12:20–12:30 Looking into the Future: Novel Therapeutics in IBD, Part 2 B3 OP260 Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n Moderated Poster \n October 18, 17:24–17:30 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0294 Efficacy, persistence, and safety of obefazimod in patients with moderately to severely active ulcerative colitis: 3-year interim analysis following dose de-escalation to 25 mg in the open-label maintenance Phase 2 study Bram Verstockt, MD, PhD Associate Professor and Principal Investigator at KU Leuven \n October 18, 17:36–17:42 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0296 Symptoms of bowel urgency and nocturnal bowel movements are linked with improvement in clinical outcomes among patients with moderately to severely active ulcerative colitis treated with obefazimod: pooled results from the 8-week David T. Rubin, MD Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago \n ABTECT Phase 3 induction trials \n E-Poster \n October 17, 9:00 – 9:00 IBD, including microscopic colitis Hall 7 PP1180 Obefazimod reduces inflammation-driven tumor burden in a murine model of colitis-associated cancer Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n\n\n\nAbout Abivax \n\nAbivax is a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases.\nBased in France and the United States, Abivax’s lead drug candidate,\nobefazimod (ABX464), is in Phase 3 clinical trials for the treatment of\nmoderately to severely active ulcerative colitis.\n\nContact:\nPatrick Malloy\nSVP, Investor Relations\nAbivax SA\npatrick.malloy@abivax.com\n+1 847 987 4878\n\nMedia Contact:\nLifeSci Communications\nKarissa Baltz, PhD\nAssociate Director\nLSC_ABIVAX@lifescicomms.com\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains forward-looking statements, forecasts and\nestimates, including those relating to the Company’s business. Words such as\n“anticipate,” “expect,” “on track,” “potential,” “will”\nand variations of such words and similar expressions are intended to identify\nforward-looking statements. These forward-looking statements include\nstatements concerning the potential therapeutic benefit of obefazimod and\nobefazimod’s potential to address significant unmet needs for patients\nliving with inflammatory bowel disease, and other statements that are not\nhistorical fact. Although Abivax’s management believes that the expectations\nreflected in such forward-looking statements are reasonable, investors are\ncautioned that forward-looking information and statements are subject to\nvarious risks, contingencies and uncertainties, many of which are difficult to\npredict and generally beyond the control of Abivax, that could cause actual\nresults and developments to differ materially from those expressed in, or\nimplied or projected by, the forward-looking information and statements. A\ndescription of these risks, contingencies and uncertainties can be found in\nthe documents filed by the Company with the French Autorité des Marchés\nFinanciers pursuant to its legal obligations including its universal\nregistration document (Document d’Enregistrement Universel) and in its\nAnnual Report on Form 20-F for the fiscal year ended December 31, 2025 filed\nwith the U.S. Securities and Exchange Commission on March 23, 2026, under the\ncaption “Risk Factors.” These risks, contingencies and uncertainties\ninclude, among other things, the uncertainties inherent in research and\ndevelopment, future clinical data and analysis, decisions by regulatory\nauthorities, such as the FDA or the EMA, regarding whether and when to approve\nany drug candidate, as well as their decisions regarding labeling and other\nmatters that could affect the availability or commercial potential of such\nproduct candidates, and the availability of funding sufficient for the\nCompany’s foreseeable and unforeseeable operating expenses and capital\nexpenditure requirements. Special consideration should be given to the\npotential hurdles of clinical and pharmaceutical development, including\nfurther assessment by the Company and regulatory agencies and IRBs/ethics\ncommittees following the assessment of preclinical, pharmacokinetic,\ncarcinogenicity, toxicity, CMC and clinical data. Furthermore, these\nforward-looking statements, forecasts and estimates are made only as of the\ndate of this press release. Readers are cautioned not to place undue reliance\non these forward-looking statements. Abivax disclaims any obligation to update\nthese forward-looking statements, forecasts or estimates to reflect any\nsubsequent changes that the Company becomes aware of, except as required by\nlaw. Information about pharmaceutical products (including products currently\nin development) that is included in this press release is not intended to\nconstitute an advertisement. This press release is for information purposes\nonly, and the information contained herein does not constitute either an offer\nto sell or the solicitation of an offer to purchase or subscribe for\nsecurities of the Company in any jurisdiction. Similarly, it does not give and\nshould not be treated as giving investment advice. It has no connection with\nthe investment objectives, financial situation or specific needs of any\nrecipient. It should not be regarded by recipients as a substitute for\nexercise of their own judgment. All opinions expressed herein are subject to\nchange without notice. The distribution of this document may be restricted by\nlaw in certain jurisdictions. Persons into whose possession this document\ncomes are required to inform themselves about and to observe any such\nrestrictions.\n\nAttachment\n* 2026_09_30_Abivax to Present Data on Obefazimod at UEG Week 2026\n(https://ml-eu.globenewswire.com/Resource/Download/8ac1be4f-8fbf-450c-a19f-b9e68d6fa0d3)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5470cd7e-c1fe-402f-8673-925c82bbd2fb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1CKvpc-20260930","title":"Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026","author":"Globe Newswire","ticker":"ABVX","created":"2026-09-30T20:05:00.622Z","tickers":["ABVX"],"exchange":"Euronext Paris","article_body":"Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG)\nWeek 2026\n\nFour oral presentations and three posters build upon Phase 3 ABTECT\nMaintenance and Induction programs in ulcerative colitis, long-term Phase 2\nfindings, and preclinical anti-fibrotic research\n\nPARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA\n(https://www.globenewswire.com/Tracker?data=eISuOI7lWu37iIKE871_O0zyV1ZATSquQxSf1637j33XLrJZmlcmA6lY8zOF_nOY1bwIBJSyYfxIdxaxu3xMDQ==)\n(Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the\n“Company”), a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases,\ntoday announced that seven scientific abstracts on obefazimod, its lead drug\ncandidate for the treatment of moderately to severely active ulcerative\ncolitis (UC), will be presented at the United European Gastroenterology (UEG)\nWeek 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain.\nThese presentations will highlight data from the Phase 3 ABTECT Maintenance\nand Induction trials in UC, long-term follow-up from the Phase 2 program in\nUC, and preclinical research on obefazimod's anti-fibrotic and anti-tumor\nactivity.\n\n\"The data being presented at UEG Week add to the growing understanding of\nobefazimod and its potential in inflammatory bowel disease,” said Marc de\nGaridel, MBA, Chief Executive Officer of Abivax. “These findings reinforce\nour confidence in obefazimod’s potential to address significant unmet needs\nfor patients living with inflammatory bowel disease.\"\n\nChris Rabbat, PhD, Chief Medical Officer of Abivax, added, \"The seven accepted\nabstracts reflect the breadth and maturity of the obefazimod program, spanning\nPhase 3 maintenance results, long-term Phase 2 efficacy and safety data, and\npreclinical findings on inflammation and fibrosis. We look forward to sharing\nthese findings with the global gastroenterology community and highlighting the\ngrowing clinical and scientific evidence supporting obefazimod.”\n\nVisit the publications page of Abivax’s website to view the presentations\nafter the conclusion of the meeting.\n\nData to be Presented:\n\n Date & Time Session Room Abstract # Title Presenter \n Oral Presentation \n October 19, 10:50–11:00 Hot Topics in Clinical GI Research D3 OP097 Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance) Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai \n October 19, 10:50–11:00 Molecular Trajectories of Disease and Drug Responses in IBD A1 OP091 Obefazimod increases miR-124 expression to consistently modulate inflammation and fibrosis across preclinical models Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n October 19, 12:00–12:10 Long-term Outcomes of Interventional Trials in IBD A2 OP107 Long-term efficacy and persistence with obefazimod after dose de-escalation to 25 mg: 3-year interim analysis in patients with moderately to severely active ulcerative colitis completing Week 144, stratified by prior advanced therapy Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai \n experience: results from the Phase 2 program \n October 20, 12:20–12:30 Looking into the Future: Novel Therapeutics in IBD, Part 2 B3 OP260 Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n Moderated Poster \n October 18, 17:24–17:30 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0294 Efficacy, persistence, and safety of obefazimod in patients with moderately to severely active ulcerative colitis: 3-year interim analysis following dose de-escalation to 25 mg in the open-label maintenance Phase 2 study Bram Verstockt, MD, PhD Associate Professor and Principal Investigator at KU Leuven \n October 18, 17:36–17:42 Outcomes from RCT in IBD (II) Hall 7 – Poster Stage 2 MP0296 Symptoms of bowel urgency and nocturnal bowel movements are linked with improvement in clinical outcomes among patients with moderately to severely active ulcerative colitis treated with obefazimod: pooled results from the 8-week David T. Rubin, MD Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago \n ABTECT Phase 3 induction trials \n E-Poster \n October 17, 9:00 – 9:00 IBD, including microscopic colitis Hall 7 PP1180 Obefazimod reduces inflammation-driven tumor burden in a murine model of colitis-associated cancer Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital \n\n\n\nAbout Abivax \n\nAbivax is a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases.\nBased in France and the United States, Abivax’s lead drug candidate,\nobefazimod (ABX464), is in Phase 3 clinical trials for the treatment of\nmoderately to severely active ulcerative colitis.\n\nContact:\nPatrick Malloy\nSVP, Investor Relations\nAbivax SA\npatrick.malloy@abivax.com\n+1 847 987 4878\n\nMedia Contact:\nLifeSci Communications\nKarissa Baltz, PhD\nAssociate Director\nLSC_ABIVAX@lifescicomms.com\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains forward-looking statements, forecasts and\nestimates, including those relating to the Company’s business. Words such as\n“anticipate,” “expect,” “on track,” “potential,” “will”\nand variations of such words and similar expressions are intended to identify\nforward-looking statements. These forward-looking statements include\nstatements concerning the potential therapeutic benefit of obefazimod and\nobefazimod’s potential to address significant unmet needs for patients\nliving with inflammatory bowel disease, and other statements that are not\nhistorical fact. Although Abivax’s management believes that the expectations\nreflected in such forward-looking statements are reasonable, investors are\ncautioned that forward-looking information and statements are subject to\nvarious risks, contingencies and uncertainties, many of which are difficult to\npredict and generally beyond the control of Abivax, that could cause actual\nresults and developments to differ materially from those expressed in, or\nimplied or projected by, the forward-looking information and statements. A\ndescription of these risks, contingencies and uncertainties can be found in\nthe documents filed by the Company with the French Autorité des Marchés\nFinanciers pursuant to its legal obligations including its universal\nregistration document (Document d’Enregistrement Universel) and in its\nAnnual Report on Form 20-F for the fiscal year ended December 31, 2025 filed\nwith the U.S. Securities and Exchange Commission on March 23, 2026, under the\ncaption “Risk Factors.” These risks, contingencies and uncertainties\ninclude, among other things, the uncertainties inherent in research and\ndevelopment, future clinical data and analysis, decisions by regulatory\nauthorities, such as the FDA or the EMA, regarding whether and when to approve\nany drug candidate, as well as their decisions regarding labeling and other\nmatters that could affect the availability or commercial potential of such\nproduct candidates, and the availability of funding sufficient for the\nCompany’s foreseeable and unforeseeable operating expenses and capital\nexpenditure requirements. Special consideration should be given to the\npotential hurdles of clinical and pharmaceutical development, including\nfurther assessment by the Company and regulatory agencies and IRBs/ethics\ncommittees following the assessment of preclinical, pharmacokinetic,\ncarcinogenicity, toxicity, CMC and clinical data. Furthermore, these\nforward-looking statements, forecasts and estimates are made only as of the\ndate of this press release. Readers are cautioned not to place undue reliance\non these forward-looking statements. Abivax disclaims any obligation to update\nthese forward-looking statements, forecasts or estimates to reflect any\nsubsequent changes that the Company becomes aware of, except as required by\nlaw. Information about pharmaceutical products (including products currently\nin development) that is included in this press release is not intended to\nconstitute an advertisement. This press release is for information purposes\nonly, and the information contained herein does not constitute either an offer\nto sell or the solicitation of an offer to purchase or subscribe for\nsecurities of the Company in any jurisdiction. Similarly, it does not give and\nshould not be treated as giving investment advice. It has no connection with\nthe investment objectives, financial situation or specific needs of any\nrecipient. It should not be regarded by recipients as a substitute for\nexercise of their own judgment. All opinions expressed herein are subject to\nchange without notice. The distribution of this document may be restricted by\nlaw in certain jurisdictions. Persons into whose possession this document\ncomes are required to inform themselves about and to observe any such\nrestrictions.\n\nAttachment\n* 2026_09_30_Abivax to Present Data on Obefazimod at UEG Week 2026\n(https://ml-eu.globenewswire.com/Resource/Download/8ac1be4f-8fbf-450c-a19f-b9e68d6fa0d3)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5470cd7e-c1fe-402f-8673-925c82bbd2fb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T20:05:00.731183476Z","server_sent_at_ms":1790798700731},"received_at":"2026-09-30T20:05:00.782Z","source_url":null},"analysis":{"id":"145917","press_release_id":"157248","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Abivax announced seven accepted abstracts on obefazimod, including four oral presentations, at UEG Week 2026 in Barcelona, October 17-20.\n\nThe data span the Phase 3 ABTECT Maintenance and Induction trials in ulcerative colitis, 3-year interim Phase 2 follow-up after dose de-escalation to 25 mg, and preclinical anti-fibrotic and anti-tumor findings.\n\nNo new efficacy data are disclosed in this release; the presentations may incrementally support the obefazimod regulatory narrative ahead of potential approval.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference visibility for obefazimod Phase 3 data -- watch UEG Week Oct 17-20 for incremental ABTECT subanalyses."},"keyFigures":{"drugName":"obefazimod (ABX464)","phaseOfTrial":"Phase 3","customDimensions":{"conference":"UEG Week 2026, Barcelona, October 17-20, 2026","accepted_abstracts":7,"oral_presentations":4}},"quotedText":"The seven accepted abstracts reflect the breadth and maturity of the obefazimod program, spanning Phase 3 maintenance results, long-term Phase 2 efficacy and safety data, and preclinical findings on inflammation and fibrosis.","namedEntities":{"people":[{"name":"Marc de Garidel","role":"CEO"},{"name":"Chris Rabbat","role":"Chief Medical Officer"},{"name":"Bruce E. Sands","role":"presenting investigator, Icahn School of Medicine at Mount Sinai"},{"name":"Silvio Danese","role":"presenting investigator, IRCCS San Raffaele Hospital"},{"name":"Bram Verstockt","role":"poster presenter, KU Leuven"},{"name":"David T. Rubin","role":"poster presenter, University of Chicago"},{"name":"Patrick Malloy","role":"SVP Investor Relations"}],"products":["obefazimod","ABX464"],"companies":[{"name":"Abivax SA","ticker":"ABVX"},{"name":"Icahn School of Medicine at Mount Sinai"},{"name":"IRCCS San Raffaele Hospital"},{"name":"KU Leuven"},{"name":"The University of Chicago"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of seven abstracts (four orals) at UEG Week 2026 covering Phase 3 ABTECT data and long-term Phase 2 follow-up in ulcerative colitis. Conference-acceptance news without new data; incremental validation for a clinical-stage asset."},"tickerRelevance":{"others":[],"primary":"ABVX"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap clinical-stage biotech","eventGravity":"conference-abstract-acceptance","sectorWeight":"IBD/UC competitive landscape","newDataDisclosed":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Abivax announced seven accepted abstracts on obefazimod, including four oral presentations, at UEG Week 2026 in Barcelona, October 17-20.\n\nThe data span the Phase 3 ABTECT Maintenance and Induction trials in ulcerative colitis, 3-year interim Phase 2 follow-up after dose de-escalation to 25 mg, and preclinical anti-fibrotic and anti-tumor findings.\n\nNo new efficacy data are disclosed in this release; the presentations may incrementally support the obefazimod regulatory narrative ahead of potential approval.","key_figures":{"drugName":"obefazimod (ABX464)","phaseOfTrial":"Phase 3","customDimensions":{"conference":"UEG Week 2026, Barcelona, October 17-20, 2026","accepted_abstracts":7,"oral_presentations":4}},"named_entities":{"people":[{"name":"Marc de Garidel","role":"CEO"},{"name":"Chris Rabbat","role":"Chief Medical Officer"},{"name":"Bruce E. Sands","role":"presenting investigator, Icahn School of Medicine at Mount Sinai"},{"name":"Silvio Danese","role":"presenting investigator, IRCCS San Raffaele Hospital"},{"name":"Bram Verstockt","role":"poster presenter, KU Leuven"},{"name":"David T. Rubin","role":"poster presenter, University of Chicago"},{"name":"Patrick Malloy","role":"SVP Investor Relations"}],"products":["obefazimod","ABX464"],"companies":[{"name":"Abivax SA","ticker":"ABVX"},{"name":"Icahn School of Medicine at Mount Sinai"},{"name":"IRCCS San Raffaele Hospital"},{"name":"KU Leuven"},{"name":"The University of Chicago"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:05:09.458Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap clinical-stage biotech","eventGravity":"conference-abstract-acceptance","sectorWeight":"IBD/UC competitive landscape","newDataDisclosed":false}},"durationMs":5432,"modelName":"glm-5.3-flashx"}}